Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Zymeworks Inc is a biotechnology business based in the US. Zymeworks shares (ZYME) are listed on the NYSE and all prices are listed in US Dollars. Zymeworks employs 383 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$29.30|
|52-week range||$24.82 - $59.03|
|50-day moving average||$36.33|
|200-day moving average||$35.48|
|Wall St. target price||$55.46|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.63|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-21.41%|
|3 months (2021-04-30)||-9.90%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
|Revenue TTM||$31.3 million|
|Gross profit TTM||$-129,583,000|
|Return on assets TTM||-21.8%|
|Return on equity TTM||-43.13%|
|Market capitalisation||$1.6 billion|
TTM: trailing 12 months
There are currently 1.5 million Zymeworks shares held short by investors – that's known as Zymeworks's "short interest". This figure is 4.3% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Zymeworks shares can be evaluated.
Zymeworks's "short interest ratio" (SIR) is the quantity of Zymeworks shares currently shorted divided by the average quantity of Zymeworks shares traded daily (recently around 476102.46153846). Zymeworks's SIR currently stands at 3.25. In other words for every 100,000 Zymeworks shares traded daily on the market, roughly 3250 shares are currently held short.
However Zymeworks's short interest can also be evaluated against the total number of Zymeworks shares, or, against the total number of tradable Zymeworks shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zymeworks's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Zymeworks shares in existence, roughly 30 shares are currently held short) or 0.0388% of the tradable shares (for every 100,000 tradable Zymeworks shares, roughly 39 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zymeworks.
Find out more about how you can short Zymeworks stock.
We're not expecting Zymeworks to pay a dividend over the next 12 months.
Over the last 12 months, Zymeworks's shares have ranged in value from as little as $24.82 up to $59.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zymeworks's is 0.9846. This would suggest that Zymeworks's shares are less volatile than average (for this exchange).
Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd. ; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd. ; Daiichi Sankyo Co. , Ltd.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.